Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $212.00
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target hoisted by research analysts at Wedbush from $181.00 to $212.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 23.21% from the stock’s current […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price target hoisted by research analysts at Wedbush from $181.00 to $212.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 23.21% from the stock’s current […]
